PHXM — Phaxiam Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €0.61m
- €12.08m
- €1.33m
Brief: Erytech Announces First Patient Enrolled In Phase 1 Trial Of Eryaspase
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:38 AM
Brief: Erytech Announces Completion Of Enrollment In TRYBECA-1 Phase 3 Trial
Brief: Erytech Pharma Announces Positive Results From Eryaspase Phase 2 Trial
NASDAQ RESUMED AT 09:52 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM
Brief: Erytech 9-Month Net Loss Widens To EUR 53.6 Mln
NASDAQ RESUMED AT 10:16 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:11 AM
Brief: Erytech Obtains Financing Of 10 Million Euros Guaranteed By French State
NASDAQ RESUMED AT 09:37 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Brief: Erytech Pharma H1 Net Loss Widens To 35 Million Euros
Brief: Erytech Pharma - Files For Shelf Of Up To $100 Mln Of Ordinary Shares
Brief: Erytech Provides Business Update And Reports Financial Results For The First Half Of 2020
Brief: Erytech Pharma Announces Implementation Of An At-The-Market Program
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:12 PM